TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Q32 Bio ( (QTTB) ) is now available.
On November 28, 2025, Q32 Bio Inc. entered into an Asset Purchase Agreement with Akebia Therapeutics, selling its Phase 2 complement inhibitor, ADX-097. This transaction, which includes an upfront payment of $7 million and additional milestone payments, is expected to extend Q32 Bio’s cash runway into the second half of 2027. The sale allows Q32 Bio to focus on advancing its bempikibart program for alopecia areata, while Akebia will handle the future development and commercialization of ADX-097. The agreement also includes potential milestone payments up to $580 million and tiered royalties on future sales of ADX-097. This strategic move strengthens Q32 Bio’s financial position and aligns with its focus on addressing significant unmet medical needs in alopecia areata.
The most recent analyst rating on (QTTB) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Q32 Bio stock, see the QTTB Stock Forecast page.
Spark’s Take on QTTB Stock
According to Spark, TipRanks’ AI Analyst, QTTB is a Neutral.
Q32 Bio’s overall stock score is low due to significant financial instability, negative revenue, and ongoing losses. The technical analysis shows mixed signals, while the valuation is unattractive with a negative P/E ratio and no dividends. These factors highlight the company’s current financial and operational challenges, suggesting a need for strategic changes to improve its financial health.
To see Spark’s full report on QTTB stock, click here.
More about Q32 Bio
Q32 Bio is a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. The company is advancing bempikibart, a fully human anti-IL-7Rα antibody, for the treatment of alopecia areata, which affects approximately 700,000 people in the United States.
Average Trading Volume: 222,772
Technical Sentiment Signal: Sell
Current Market Cap: $26.95M
Find detailed analytics on QTTB stock on TipRanks’ Stock Analysis page.